More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma by Jun, Tomi W. et al.
Liver International. 2018;38:895–902.	 wileyonlinelibrary.com/journal/liv	 	 | 	895© 2017 John Wiley & Sons A/S. 




C A N C E R
More advanced disease and worse survival in cryptogenic 
compared to viral hepatocellular carcinoma
Tomi W. Jun1 | Ming-Lun Yeh2 | Ju Dong Yang3 | Vincent L. Chen1,4 | Pauline Nguyen1 |  
Nasra H. Giama3 | Chung-Feng Huang2 | Ann W. Hsing5 | Chia-Yen Dai2 |  
































Methods:	We	 conducted	 a	 retrospective	 cohort	 study	 involving	 3878	 consecutive	
HCC	patients	seen	at	two	tertiary	centres	in	the	United	States	and	one	in	Taiwan	from	
2004	 to	 2014.	We	 compared	 the	 clinical	 characteristics,	 treatment	 and	 survival	 of	
patients	 by	 underlying	 aetiology:	 cryptogenic	 (n	=	696),	 HBV	 (n	=	1304)	 or	 HCV	
(n	=	1878).
Results:	Cirrhosis	was	present	in	66.8%	of	the	cryptogenic	HCC	patients,	compared	
with	 74.7%	 of	 HBV-	related	 HCC	 (HBV-	HCC)	 (P = .001)	 and	 85.9%	 of	 HCV-	HCC	
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in	 patients	without	 a	 known	 history	 of	 cirrhosis.10-15	 Some	 studies	



















2  | PATIENTS AND METHODS
2.1 | Study design and patient population
This	retrospective	cohort	study	 involved	3878	consecutive	cases	of	






the	 Mayo	 Clinic	 in	 Rochester,	 and	 Kaohsiung	 Medical	 University	
Hospital.	An	exemption	from	informed	consent	was	granted	because	
of	the	minimal	risk	posed	to	participants	in	this	chart	review	study.


















(platelets	 <120	000/μL,	 splenomegaly,	 ascites	 or	 gastroesophageal	
varices	on	 imaging)	or	 if	 they	had	hepatic	decompensation	 (hepatic	
encephalopathy,	 ascites,	 variceal	 bleeding)	within	6	months	of	HCC	
diagnosis.
2.3 | Tumour staging and survival outcomes
Tumour	stage	was	assessed	by	the	Milan	criteria	 for	 transplant	and	
the	Barcelona	clinic	liver	cancer	(BCLC)	staging	system.	Tumour	size	
















HCC	had	worse	overall	 survival	 despite	often	 receiving	
treatments	with	curative	intent.
•	 Cryptogenic	 aetiology	 of	HCC	was	 not	 an	 independent	
predictor	 of	 survival	 after	 adjusting	 for	 factors	 such	 as	
stage	of	disease	and	treatment	strategy.






predictor	 variable	 was	 HCC	 aetiology	 (HBV,	 HCV	 or	 cryptogenic).	
Secondary	predictors	 included	ethnicity,	cirrhosis,	 tumour	stage	and	
treatment	 strategy.	 Treatments	 such	 as	 liver	 transplantation,	 sur-
gical	 resection	 and	 radiofrequency	 ablation	 (RFA)	 were	 considered	
treatments	with	curative	 intent,	while	treatments	such	as	transcath-
eter	 arterial	 chemoembolization	 (TACE),	 radioembolization	 (RE)	 and	
sorafenib	were	considered	palliative.	Univariate	and	multivariate	sur-
vival	models	were	constructed	using	Cox	proportional	hazards	models.	
Relevant	variables	 that	were	 significant	 (defined	as	 association	with	







3.1 | Baseline patient clinical characteristics



























Despite	 having	 more	 advanced	 tumours	 at	 presentation,	 cryp-
togenic	 HCC	 patients	 were	 significantly	 more	 likely	 to	 receive	
TABLE  1 Baseline	patient	clinical	characteristics,	by	hepatocellular	carcinoma	(HCC)	aetiology
Cryptogenic (N = 696) HBV (N = 1304) P value HCV (N = 1878) P value
Overall 
(N = 3878)
Agea	(y) 67.2	±	13.4 58.3	±	12.2 <.001 63.0	±	9.9 <.001 62.2	±	11.8
Male 440	(63.2%) 1074	(82.4%) <.001 1248	(66.5%) .125 2762	(71.2%)
Asian 317	(45.6%) 1251	(95.9%) <.001 1040	(55.4%) <.001 2608	(67.3%)
US	site 412	(59.2%) 349	(26.8%) <.001 1054	(56.1%) .162 1815	(46.8%)
History	of	regular	alcohol	use 0	(0%) 380	(29.3%) <.001 801	(43.0%) <.001 1181	(30.7%)
Body	mass	indexa	(kg/m2) 27.7	±	6.2 24.4	±	4.0 <.001 26.0	±	5.3 <.001 25.8	±	5.2
Hypertension	(HTN) 354	(58.2%) 403	(31.7%) <.001 855	(47.1%) <.001 1612	(43.6%)
Diabetes	(DM) 278	(45.7%) 299	(23.5%) <.001 594	(32.8%) <.001 1171	(31.8%)
≥2	of	obesityb,	HTN,	DM 297	(44.8%) 295	(22.9%) <.001 604	(32.5%) <.001 1196	(31.4%)
Coronary	artery	disease 130	(21.5%) 40	(3.1%) <.001 108	(6.0%) <.001 278	(7.6%)
Symptomatic	at	diagnosis 395	(58.0%) 491	(39.1%) <.001 670	(42.8%) <.001 1556	(44.4%)
Cirrhosis 338	(66.8%) 919	(74.7%) .001 1497	(85.9%) <.001 2754	(79.2%)
Ascites 198	(30.8%) 345	(27.2%) .099 442	(24.3%) .001 985	(26.4%)
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treatments	 with	 curative	 intent	 compared	 to	 patients	 with	 viral	
aetiologies	 (31.5%	 for	 cryptogenic	 HCC,	 23.0%	 for	 HBV-	HCC;	







for	 the	 cryptogenic	 group,	 1.6	years	 (SD:	 2.07	years)	 for	 the	 HBV	
group	and	1.8	years	(SD:	2.00	years)	for	the	HCV	group.	The	rate	of	
















HBV-	HCC	(67.3%,	P < .001)	or	HCV-	HCC	(45.2%,	P = .02)	(Figure	1D).
TABLE  2 Baseline	patient	laboratory	characteristics,	by	hepatocellular	carcinoma	(HCC)	aetiology
Cryptogenic (N = 696) HBV (N = 1304) P value HCV (N = 1878) P value Overall (N = 3878)
Platelet countb	(K/μL) 183.5	(IQR	121-	259) 152	(IQR	104-	217) <.001 114	(IQR	76-	163) <.001 137	(IQR	89-	197)
Total	bilirubinb	(mg/dL) 0.9	(IQR	0.6-	1.5) 1	(IQR	0.7-	1.5) .003 1.1	(IQR	0.7-	1.7) <.001 1	(IQR	0.7-	1.6)
Albumina	(g/dL) 3.5	±	0.6 3.5	±	0.6 .323 3.3	±	0.6 <.001 3.4	±	0.6
International	normalized	
ratiob
1.1	(IQR	1-	1.2) 1.1	(IQR	1-	1.2) <.001 1.1	(IQR	1-	1.3) <.001 1.1	(IQR	1-	1.2)
Aspartate	transaminaseb 
(U/L)
55	(IQR	36-	95) 59	(IQR	38-	108) .068 80.5	(IQR	52-	124) <.001 69	(IQR	43-	115)
Alanine transaminaseb 
(U/L)
42	(IQR	27-	61) 48	(IQR	34-	75) <.001 67	(IQR	40-	107) <.001 69	(IQR	43-	115)
Log10 AFP
b	(ng/dL) 3.3	(IQR	1.6-	7.2) 4.3	(IQR	2.3-	6.9) <.001 3.7	(IQR	2.3-	6) .008 3.8	(IQR	2.2-	6.4)
CTP	Ac 124	(47.7%) 508	(62.9%) <.001 719	(56.0%) .027 1351	(57.5%)
CTP	B 113	(43.5%) 247	(30.6%) 488	(38.1%) 848	(36.1%)
CTP	C 23	(8.9%) 53	(6.6%) 76	(5.9%) 152	(6.5%)








(N = 696) HBV (N = 1304) P value HCV (N = 1878) P value Overall (N = 3878)
Max.	tumour	size	(cm) 6.0	(IQR	3.4-	9.7) 3.9	(IQR	2.4-	7.3) <.001 3.2	(IQR	2.1-	5.2) <.001 3.7	(IQR	2.3-	6.5)
Multifocal 276	(44.5%) 342	(33.5%) <.001 602	(35.0%) <.001 1220	(36.3%)
Vascular	invasion 127	(19.7%) 203	(17.9%) .347 232	(13.0%) <.001 562	(15.8%)
Extrahepatic	
metastasis
107	(16.2%) 140	(11.2%) .002 123	(6.7%) <.001 370	(9.9%)
Within	Milan	criteria 187	(28.2%) 530	(45.4%) <.001 974	(55.8%) <.001 1691	(47.3%)
BCLC	C/D 214	(46.8%) 323	(35.5%) <.001 363	(26.4%) <.001 900	(32.8%)
BCLC,	Barcelona	clinic	liver	cancer;	HBV,	hepatitis	B	virus;	HCV,	hepatitis	C	virus.
P	values	are	for	the	comparison	to	cryptogenic.
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3.5 | Predictors of survival
Favourable	predictors	of	5-	year	survival	in	univariate	Cox	propor-
tional	 hazard	models	 included	 female	 gender,	 younger	 age,	Asian	
or	Hispanic	 ethnicity	 (compared	 to	 Caucasian	 ethnicity),	 absence	
of	 cirrhosis,	 absence	 of	 coronary	 artery	 disease	 (CAD),	 meeting	
Milan	 criteria,	 curative	 or	 palliative	 treatments	 (compared	 to	 no	
treatment)	and	viral	aetiology	 (Table	5).	 In	 the	multivariate	analy-





3.6 | Analysis by United States vs Taiwan sites
The	 distribution	 of	 aetiologies	 and	 treatment	 strategies	 differed	
between	the	US	and	Taiwan	sites.	The	majority	of	the	cryptogenic	
and	HCV-	HCC	patients	were	 from	 the	United	States	whereas	 the	
majority	of	the	HBV-	HCC	patients	were	from	Taiwan.	The	US	sites	
were	more	likely	to	perform	curative	treatments	such	as	transplant	
(13.9%	vs	0.1%,	P < .001),	resection	(19.6%	vs	12.7%,	P < .001)	and	
RFA	 (11.3%	 vs	 6.4%,	 P < .001)	 (Table	 S1).	 However,	 cryptogenic	
HCC	patients	had	worse	survival	than	viral	HCC	patients	at	both	US	
and	Taiwan	sites.	At	the	US	sites,	5-	year	overall	survival	was	16.6%	
for	 the	 cryptogenic	HCC	 patients	 compared	 to	 39.8%	 and	 27.9%	
for	the	HBV-	HCC	and	HCV-	HCC	patients	respectively	(P < .001	for	
both)	 (Figure	S2A).	At	 the	Taiwan	site,	5-	year	overall	 survival	was	
15.6%	for	the	cryptogenic	HCC	patients,	27.5%	for	the	HBV-	HCC	
patients	 (P = .03)	 and	 26.2%	 for	 the	HCV-	HCC	 patients	 (P < .001)	
(Figure	S2B).
3.7 | Hepatocellular carcinoma surveillance





Of	 these,	 330	 had	 cryptogenic	 HCC,	 160	 had	 HBV-	HCC	 and	
494	 had	 HCV-	HCC.	 HCV-	HCC	 patients	 had	 a	 significantly	 higher	
rate	of	surveillance	than	cryptogenic	HCC	patients	(38.3%	vs	18.8%,	














In	 this	 large	study	of	3878	HCC	patients,	we	 found	that	 relative	 to	
patients	 with	 HBV-	 or	 HCV-	HCC,	 patients	 with	 cryptogenic	 HCC	




(N = 696) HBV (N = 1304) P value HCV (N = 1878) P value
Overall 
(N = 3878)
Transplant 13	(3.2%) 21	(1.7%) .062 132	(8.3%) <.001 166	(5.1%)
Resection 124	(26.6%) 204	(16.5%) <.001 180	(11.2%) <.001 508	(15.3%)
RFA 39	(9.3%) 76	(6.2%) .029 154	(9.5%) .888 269	(8.2%)
TACE 252	(54.6%) 651	(52.2%) .381 1039	(61.1%) .011 1942	(56.9%)
RE 6	(5.2%) 10	(3.5%) .449 46	(6.0%) .727 62	(5.3%)
Sorafenib 11	(2.8%) 26	(2.1%) .447 37	(2.3%) .621 74	(2.3%)
Curative	intent 174	(31.5%) 291	(23.0%) <.001 448	(26.0%) .011 913	(25.8%)
Primary treatment
Transplant 13	(2.4%) 21	(1.7%) .005 132	(7.7%) <.001 166	(4.7%)
Resection/RFA 161	(29.1%) 270	(21.4%) 316	(18.3%) 747	(21.1%)
TACE/RE 243	(43.9%) 622	(49.2%) 893	(51.7%) 1758	(49.6%)
Sorafenib 6	(1.1%) 20	(1.6%) 16	(0.9%) 42	(1.2%)











resection	 is	 more	 commonly	 offered	 to	 this	 group	 of	 patients	 be-
cause	cirrhosis	is	less	prevalent	compared	to	patients	with	viral	HCC.	


















lance	 in	 cryptogenic	HCC	 patients.	 Firstly,	 one-	third	 of	 cryptogenic	
HCC	patients	in	our	cohort	did	not	have	cirrhosis	and	hence	would	not	
have	met	current	criteria	for	HCC	surveillance.	Secondly,	prior	stud-
ies	 have	 reported	 lower	 HCC	 surveillance	 rates	 for	 NAFLD-	related	
cirrhosis	 compared	 to	 other	 forms	 of	 cirrhosis,	 perhaps	 because	 of	
lack	of	awareness	about	the	risk	of	NAFLD	progressing	to	HCC.14-16 
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that	has	been	assembled	to	compare	viral	and	non-	viral	HCC.	Our	data	
are	also	consistent	with	previous	 studies	which	 found	 that	NAFLD-	
HCC	often	arises	in	patients	without	clinically	apparent	cirrhosis	and	
that	NAFLD-	HCC	tends	 to	present	with	 larger	 tumours	and	at	 later	
stages.10-16,23-25	A	nationwide	survey	in	Japan	found	cirrhosis	in	62%	






























ent	 in	patients	with	 advanced	 liver	 disease.	 It	 should	 also	be	noted	
that	we	did	not	evaluate	 for	occult	HBV	 infection,	which	 is	defined	
as	HBV	DNA	 in	 the	 liver	 of	 a	 patient	with	 negative	HBsAg,	Occult	
Univariate Multivariate
Predictor HR (95% CI) P value HR (95% CI) P value
Male 1.14	(1.02-	1.28) .017 0.96	(0.83-	1.11) .593
Age 1.01	(1.00-	1.01) .019 1.00	(1.00-	1.01) .492
Ethnicitya
Caucasian 1 Reference 1 Reference
Asian	(Taiwan) 0.89	(0.79-	1.00) .049 0.82	(0.68-	0.99) .039
Asian	(US) 0.59	(0.50-	0.69) <.001 0.51	(0.40-	0.64) <.001
African-	American 1.06	(0.74-	1.52) .733 0.89	(0.52-	1.51) .657
Hispanic 0.69	(0.56-	0.86) .001 0.59	(0.45-	0.77) <.001




1.37	(1.15-	1.63) <.001 1.17	(0.87-	1.59) .300
MELD 1.05	(1.04-	1.06) <.001 1.05	(1.04-	1.06) <.001
Within	Milan	
criteria
0.30	(0.27-	0.34) <.001 0.33	(0.29-	0.38) <.001
HCC	Surveillance 0.54	(0.42-	0.70) <.001
Primary treatment
No	treatment 1 Reference 1 Reference
Curative 0.09	(0.08-	0.11) <.001 0.10	(0.08-	0.12) <.001
Palliative 0.33	(0.29-	0.36) <.001 0.35	(0.30-	0.40) <.001
Aetiology
Cryptogenic 1 Reference 1 Reference
HBV 0.69	(0.60-	0.80) <.001 0.99	(0.80-	1.22) .901
























ity,	 and	disability-	adjusted	 life-	years	 for	32	cancer	groups,	1990	 to	
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